TIVC

8-K - Tivic Health Systems, Inc. (0001787740) (Filer)

Ticker Symbol to Change from TIVC to VBIO Effective April 28, 2026; Company Advancing Entolimod™ Toward BARDA Funding and Strategic National Stockpile Procurement While Velocity Bioworks CDMO Builds Independent Revenue BaseSAN ANTONIO, April 23, 2026 /PRNewswire/ -- Tivic Health Systems, Inc. (NASDAQ:TIVC) today announced it is changing its corporate name to Valion Bio, Inc. and its Nasdaq ticker symbol from TIVC to VBIO, effective at market open on Tuesday, April 28, 2026. The CUSIP number for the company's common stock will remain unchanged. The rebrand is not merely cosmetic.

PRE 14A - Tivic Health Systems, Inc. (0001787740) (Filer)

4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

EFFECT - Tivic Health Systems, Inc. (0001787740) (Filer)

424B3 - Tivic Health Systems, Inc. (0001787740) (Filer)

SAN ANTONIO, April 15, 2026 /PRNewswire/ -- Tivic Health Systems, Inc. (NASDAQ:TIVC), a clinical-stage immunotherapeutics company, today announced it has been selected to present at the U.S. Department of War's Tech Watch program on May 7, 2026. The Tech Watch initiative identifies emerging technologies with high-value defense and dual-use applications. Tivic Health will present its Entolimod™ TLR5 agonist lead drug candidate and its plans for an oral transmucosal delivery program for Entolimod™ — a delivery concept the Company believes has compelling and immediate relevance for

S-1 - Tivic Health Systems, Inc. (0001787740) (Filer)

4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

MIAMI, April 01, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 91st Emerging Growth Conference on April 1 & 2, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Day 1 – Presenting TodayWednesday, April 1, 2026 9:00Virtual Lobby opens.Register for the Conference. If you a

SAN ANTONIO, TX / ACCESS Newswire / March 31, 2026 / Tivic Health Systems, Inc. (NASDAQ:TIVC), a clinical-stage immunotherapeutics company, today announced it has received a formal Request for Information (RFI) from the Ukrainian Ministry of Health. The RFI initiates the formal evaluation of Entolimod™ Tivic's late-stage Toll-like Receptor 5 (TLR5) agonist for potential inclusion in Ukraine's national strategic reserves as a countermeasure against Acute Radiation Syndrome (ARS). Additionally, the Ukrainian Ministry of Health has requested to schedule a pre-submission meeting for Entolimod™."Tivic's Entolimod, from our TLR5 platform, has catalyzed significant interest from international gover

MIAMI, March 31, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 91st Emerging Growth Conference on April 1 & 2, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Day 1 - WednesdayApril 1, 2026 9:00Virtual Lobby opens.Register for the Conference. If you already registered, go back to

10-K - Tivic Health Systems, Inc. (0001787740) (Filer)

Presentation will Cover Recent Corporate Milestones Including Securing Agreement with NIAIDSAN ANTONIO, TX / ACCESS Newswire / March 27, 2026 / Tivic Health® Systems, Inc. (NASDAQ:TIVC), a clinical-stage immunotherapeutics company, today announced that its newly appointed Chief Executive Officer, Michael K Handley, will deliver a corporate update at the Emerging Growth Virtual Conference taking place April 1-2, 2026.During the virtual conference, Mr. Handley will highlight key milestones, including the company's recent agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to sponsor and conduct a preclinical study evaluat

Armed Forces Radiobiology Research Institute (AFRRI) Will Conduct the Gastrointestinal Acute Radiation Syndrome (GI-ARS) StudySAN ANTONIO, TX / ACCESS Newswire / March 26, 2026 / Tivic Health Systems Inc. (NASDAQ:TIVC), a clinical-stage immunotherapeutics company, today announced it has entered into an agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to sponsor and conduct a series of preclinical studies evaluating Entolimod™ for gastrointestinal acute radiation syndrome (GI-ARS).The program is expected to support Tivic's development strategy for Entolimod™ as a medical countermeasure for acute radiation syndrome (AR

8-K - Tivic Health Systems, Inc. (0001787740) (Filer)

Completes Strategic Transformation into an Immunotherapy Company and Continues to Advance Entolimod Platform Toward Potential Funding PartnershipsConference Call to be Held Today at 1:30 PM PT / 4:30 PM ETSAN ANTONIO, TX / ACCESS Newswire / March 25, 2026 / Tivic Health Systems, Inc. (NASDAQ:TIVC), a development-stage immunotherapy company, today reported financial and operational results for the year ended December 31, 2025, and provided a business update highlighting the company's strategic transformation and focus on the development of its Entolimod™ platform."2025 was a defining year for Tivic as we marked our transformation into a focused immunotherapy company anchored by Entolimod and

SAN ANTONIO, TX / ACCESS Newswire / March 24, 2026 / Tivic Health Systems (NASDAQ:TIVC)Dear Valued Shareholders,As I assume the role of Chief Executive Officer at Tivic, my immediate priority is to establish a transparent dialogue with you regarding our current standing, our strategic pivot, and the long-term vision we are executing.First, I want to thank the Board of Directors for their confidence and support. Some of you recognize me from my time as Chief Executive Officer of Statera Biopharma, where I led the advancement of Entolimod™, our Toll-like Receptor 5 (TLR5) agonist. Over the past year, as Tivic's Chief Operating Officer and President of Biopharma, I have continued to advance the

8-K - Tivic Health Systems, Inc. (0001787740) (Filer)

SAN ANTONIO, TX / ACCESS Newswire / March 20, 2026 / Tivic Health Systems, Inc. (NASDAQ:TIVC), a late-stage immunotherapeutics company, today announced that it will report its year-end financial results for 2025 via pre-recorded conference call and webcast on Wednesday, March 25, 2026 at 1:30 PM PT / 4:30 PM ET.Conference Call and Webcast InformationTeleconference Details:Toll Free: 888-506-0062International: 973-528-0011Participant Access Code: 910220Webcast Linkhttps://www.webcaster5.com/Webcast/Page/2865/53678An audio replay of the call will be available for the next 90 days from the investor page on the Tivic website at https://tivichealth.com/investor/.About TivicTivic Health's biologic

4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

8-K - Tivic Health Systems, Inc. (0001787740) (Filer)

8-K - Tivic Health Systems, Inc. (0001787740) (Filer)

8-K - Tivic Health Systems, Inc. (0001787740) (Filer)

SAN FRANCISCO, CA / ACCESS Newswire / March 4, 2026 / Tivic Health Systems, Inc. (NASDAQ:TIVC) ("Tivic" or the "Company"), a late-stage immunotherapeutics company, today announced that its Board of Directors has appointed Michael K. Handley as Chief Executive Officer of Tivic, effective immediately. Mr. Handley succeeds Jennifer Ernst, who has served as CEO since its founding in 2016 and is stepping down from the CEO role as the Company enters its next chapter. Ms. Ernst will continue to support the Company through this strategic transition.The appointment of Mr. Handley marks a decisive shift in Tivic's strategic direction as the Company aligns its leadership and resources toward the high-g